Treatment of Granulomatosis with Polyangiitis (Wegener's Granulomatosis)
For newly diagnosed GPA with severe/organ-threatening disease, use rituximab or cyclophosphamide combined with glucocorticoids for remission induction, followed by rituximab or azathioprine/methotrexate for maintenance therapy. 1, 2
Remission Induction Therapy
First-Line Options
Rituximab has emerged as equally effective to cyclophosphamide and is now a preferred option, particularly for women of childbearing age due to lower risks of infertility and malignancy 3, 4. Both the 2024 EULAR and 2021 ACR/Vasculitis Foundation guidelines support rituximab as first-line therapy 1, 2.
Glucocorticoids are essential in combination with either agent:
- Standard dosing: 1 mg/kg/day prednisone equivalent
- Consider IV methylprednisolone for severe presentations
- The optimal starting dose remains under investigation, with studies examining lower doses (0.5 mg/kg/day) 1
Treatment Selection Algorithm
Choose rituximab over cyclophosphamide when:
- Patient is of childbearing age (either sex)
- Concern for fertility preservation
- History of or high risk for malignancy
- Patient preference for potentially safer long-term profile
Cyclophosphamide remains appropriate when:
- Rituximab is unavailable or contraindicated
- Fulminant disease requiring rapid control
- Prior rituximab failure
Disease Severity Stratification
The approach differs based on severity:
Severe/organ-threatening disease (renal involvement, pulmonary hemorrhage, CNS involvement):
- Rituximab OR cyclophosphamide + glucocorticoids
- Consider plasma exchange for severe renal disease or pulmonary hemorrhage (though evidence is mixed) 2
Non-severe disease (limited upper airway, non-organ threatening):
- Methotrexate + glucocorticoids may be sufficient
- Rituximab if methotrexate contraindicated 2
Maintenance Therapy
After achieving remission (typically 3-6 months), transition to maintenance immunosuppression to prevent relapse:
Preferred Maintenance Options
- Rituximab: Increasingly favored, with repeat dosing schedules under investigation 1, 5
- Azathioprine: Traditional maintenance agent
- Methotrexate: Alternative to azathioprine
- Mycophenolate mofetil: Third-line option
Duration of maintenance therapy: Typically 18-24 months minimum, though optimal duration remains undefined and relapse risk is high 5, 6. The 2024 EULAR guidelines acknowledge this as a key research priority 1.
Adjunctive Therapies
Pneumocystis jirovecii prophylaxis is conditionally recommended for patients receiving cyclophosphamide or rituximab 2. Trimethoprim-sulfamethoxazole serves dual purposes:
- PCP prophylaxis during intensive immunosuppression
- May reduce disease relapse risk (though optimal duration unclear) 3
Special Populations
Pregnancy:
- Avoid cyclophosphamide and rituximab
- Intravenous immunoglobulin (IVIG) can be used as bridge therapy until conventional agents can be safely administered 2, 3
- Glucocorticoids remain relatively safe
Renal transplantation:
- Patients with stage 5 CKD in remission should be evaluated for transplantation
- Outcomes are similar to other transplant recipients
- Disease relapse in transplanted kidney is rare 2
Common Pitfalls
Critical caveats to avoid:
Don't delay treatment waiting for biopsy confirmation in severely ill patients—clinical diagnosis with ANCA positivity may suffice to initiate therapy
ANCA-negative GPA exists (10-20% of cases)—don't exclude diagnosis based solely on negative ANCA 7, 8
Don't stop maintenance therapy prematurely—relapse rates are high, and optimal duration extends beyond initial remission 5, 6
Monitor for treatment-related toxicity: Cyclophosphamide carries risks of hemorrhagic cystitis, infertility, and malignancy; rituximab requires monitoring for hypogammaglobulinemia and infection risk
Proteinase-3 (PR3) ANCA positivity is more specific for GPA than MPO-ANCA and may guide future classification 8, 9
Emerging Therapies
The 2024 EULAR guidelines identify several agents under investigation 1:
- Avacopan (C5a receptor antagonist): May reduce or replace glucocorticoid requirement
- Mepolizumab (IL-5 inhibitor): Primarily for EGPA but under study
- JAK inhibitors: Novel immunomodulators in early investigation